Powered by CRISPR and synthetic biology, Sherlock's proprietary engineering biology tools form the foundation of its decentralized diagnostic platform for DNA and RNA detection. In 2020 the company made history with the first FDA-authorized use of CRISPR technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/10/22 | $80,000,000 | Series B |
Albany Capital Catalio Capital Good Ventures Illumina Ventures Northpond Ventures Novalis LifeSciences  | undisclosed |
